{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:05Z","timestamp":1792120805669,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bneo.2024.100056","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T07:08:01Z","timestamp":1730531281000},"page":"100056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-4379","authenticated-orcid":false,"given":"Tim C.P.","family":"Somervaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-920X","authenticated-orcid":false,"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7093","authenticated-orcid":false,"given":"Andrew","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa M.","family":"Ayala Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-1399","authenticated-orcid":false,"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-6062","authenticated-orcid":false,"given":"Akshanth R.","family":"Polepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1146-8253","authenticated-orcid":false,"given":"Jalaja","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bneo.2024.100056_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bjhh.2014.10.001","article-title":"Myeloproliferative neoplasms and the JAK\/STAT signaling pathway: an overview","volume":"37","author":"de Freitas","year":"2015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.bneo.2024.100056_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-5-2","article-title":"Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis","volume":"5","author":"Tognon","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100056_bib3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100056_bib4","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100056_bib5","first-page":"89","article-title":"Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"Mughal","year":"2014","journal-title":"Int J Gen Med"},{"issue":"suppl 5","key":"10.1016\/j.bneo.2024.100056_bib6","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Vannucchi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bneo.2024.100056_bib7","series-title":"Jakafi (ruxolitinib) tablets. Prescribing information","year":"2023"},{"issue":"13","key":"10.1016\/j.bneo.2024.100056_bib11","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bneo.2024.100056_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2024.100056_bib13","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2024.100056_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2018-02-785923","article-title":"How I treat myelofibrosis after failure of JAK inhibitors","volume":"132","author":"Pardanani","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100056_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.84","article-title":"Definition and management of ruxolitinib treatment failure in myelofibrosis","volume":"4","author":"Pardanani","year":"2014","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.bneo.2024.100056_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114363","article-title":"JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL","volume":"10","author":"Guo","year":"2015","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.bneo.2024.100056_bib17","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.bneo.2024.100056_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-5339","article-title":"BCL2A1 is expressed in myelofibrosis specimens and JAK2-mutated UKE-1 cells, yet does not inhibit synergistic cell killing by BCL-XL inhibitor navitoclax plus JAK1\/2 inhibitors, including ruxolitinib [abstract]","volume":"82","author":"Refici","year":"2022","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.bneo.2024.100056_bib21","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2024.100056_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.bneo.2024.100056_bib23","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100056_bib24","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jpba.2005.02.037","article-title":"Guidelines from the International Conference on Harmonisation (ICH)","volume":"38","author":"Branch","year":"2005","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"21","key":"10.1016\/j.bneo.2024.100056_bib25","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bneo.2024.100056_bib26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.bneo.2024.100056_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100056_bib28","first-page":"1128","article-title":"European Consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bneo.2024.100056_bib30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bneo.2024.100056_bib31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.bneo.2024.100056_bib32","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.34986","article-title":"New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: focus on clinical development of BCL-X(L) \/BCL-2 inhibition with navitoclax","volume":"129","author":"Pemmaraju","year":"2023","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2024.100056_bib33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100056_bib34","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bneo.2024.100056_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.HS9.0000843672.56808.41","article-title":"S195: MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor","volume":"6","author":"Verstovsek","year":"2022","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.bneo.2024.100056_bib36","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100056_bib37","article-title":"Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis","volume":"142","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100056_bib38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100056_bib39","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bneo.2024.100056_bib40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2024.100056_bib41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bneo.2024.100056_bib42","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100056_bib43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100056_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-139247","article-title":"A\u00a0phase 3, open-label, randomized study evaluating the efficacy and safety of navitoclax plus ruxolitinib versus best available therapy in patients with relapsed\/refractory myelofibrosis (TRANSFORM-2)","volume":"136","author":"Dilley","year":"2020","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:59:48Z","timestamp":1745024388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2950328024000566"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100056","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology.","name":"copyright","label":"Copyright"}],"article-number":"100056"}}